Healthcare | May 08, 2024
Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia
Investing in Malaysia's largest clinic operator to expand the healthcare business
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
With this, for all our USFDA facilities, EIRs are in place
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
ORACEA is a trademark of Galderma Holdings, S.A.
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
